MSLN and neoplasm: Wang and colleagues developed an anti-mesothelin CAR T that co-expresses the chemokine receptor CCR2b for treatment of preclinical models of non-small-cell lung carcinoma which demonstrated superior tumor infiltration compared to the Msln-CAR alone (51).